Rodman & Renshaw Initiates Coverage On Alto Neuroscience with Buy Rating, Announces Price Target of $43
Portfolio Pulse from Benzinga Newsdesk
Rodman & Renshaw initiates coverage on Alto Neuroscience (NYSE:ANRO) with a Buy rating and sets a price target of $43.
June 21, 2024 | 9:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rodman & Renshaw has initiated coverage on Alto Neuroscience with a Buy rating and a price target of $43, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $43 by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100